“Probing Immunity in Tissues and Tumors Using High Plex 2D and 3D Imaging”
Dr. Ronald N. Germain, NIH/NIAID.
Ronald N. Germain received his M.D. and Ph.D. from Harvard University in 1976. Since then he has investigated basic immunobiology, first on the faculty at Harvard, then at NIAID, NIH. He has contributed to understanding MHC class II molecules, antigen processing, and T cell recognition, more recently pioneering analysis of the immune system using dynamic and static in situ microscopy. He has published more than 400 scholarly research papers and reviews and trained more than 80 fellows. Among other honors, he has been elected to the National Academy of Medicine, the National Academy of Sciences, EMBO, AAAS, the American Academy of Arts and Sciences, the Kunkel Society, named a Distinguished Fellow by the American Association of Immunologists, received the AAI Excellence in Mentoring and Meritorious Career Awards, and designated a Distinguished Investigator by NIH.
“Novel tools to modify and steer T cell recognition”
Dr. Sine R. Hadrup, Technical University of Denmark
Sine Reker Hadrup is Professor and Head of Experimental and Translational Immunology at the Technical University of Denmark (DTU). Her research centers on antigen-specific T cell responses, particularly in cancer, autoimmunity, and infectious diseases, with a strong emphasis on developing innovative technologies to interrogate immune recognition.
She has pioneered multiplexed T cell detection approaches, including DNA barcode-based systems that enable simultaneous profiling of thousands of antigen-specific T cells, transforming how immune responses are assessed. Her work has provided key insights into tumor–immune interactions, mechanisms of response to immunotherapy, and the role of T cell specificity in clinical outcomes.
Prof. Hadrup has authored more than 120 peer-reviewed publications and is a recognized leader in the field, with major awards including ERC grants and a Novo Nordisk Foundation Challenge Grant. In addition to her academic contributions, she has co-founded several biotech companies translating immunological innovations into clinical applications.
Her work bridges technological innovation and clinical translation, with the goal of enabling more precise and effective T cell–based immunotherapies.